Cardiovascular Disease research hub

A Phase III Study to Assess the Effect of AZD0780 on LDL-C in Patients With Clinical ASCVD or at Risk for a First ASCVD Event

This study looks at a new drug, AZD0780, for people with heart disease or who are at risk of it, and who have high 'bad' cholesterol (LDL-C). We want to see if AZD0780 safely lowers this cholesterol.

REDEFINE 3: A Research Study to See the Effects of CagriSema in People Living With Diseases in the Heart and Blood Vessels

This study, called REDEFINE 3, investigates a new medicine, CagriSema, for people with heart and blood vessel diseases. It aims to see if CagriSema can reduce the risk of serious events like heart attacks and strokes.

Ultimaster Nagomi™ Sirolimus Eluting Coronary Stent System in Complex PCI Patients

This study looks at how well a special new heart stent, called Ultimaster Nagomi™, works in people with complex heart problems. It aims to see if it helps reduce serious issues like heart attacks or needing another procedure after one year.

Investigating the Effects of Green Tea on Blood Viscosity

This study looks at how green tea affects blood thickness in healthy people aged 65 and over. Researchers want to see if green tea can improve blood flow, which might help reduce the risk of heart and blood vessel problems. They will measure blood thickness before and after drinking green tea.

A Phase III Study of AZD0780 on Major Adverse CV Events in Patients With a History of ASCVD Events or at High Risk for a First Event

This study is looking into a new medication called AZD0780. It aims to see if this medicine can lower the risk of serious heart problems like heart attacks or strokes in people who have already had them, or in those at high risk of having one for the first time.

A Double-blind, Randomized,Placebo-controlled, Multicenter Study Assessing Olpasiran Use to Prevent First Major Cardiovascular Events in Participants with Elevated Lipoprotein(a)

This study is looking at a new medicine called Olpasiran. It aims to see if Olpasiran can help prevent serious heart problems like heart attacks in people who have high levels of a specific fat in their blood called lipoprotein(a).

Efficacy and safety of SP16 in preventing Acute Kidney Injury in at-risk subjects with chronic kidney disease undergoing elective cardiac surgery using the heart-lung-machine: A prospective, randomized, double-blind, placebo-controlled clinical trial (EASE-AKI)

This study looks at a new treatment, SP16, to see if it can protect kidneys in people with existing kidney problems who are having heart surgery. It aims to prevent a complication called Acute Kidney Injury (AKI) that can happen after surgery.

Impact of Oral Semaglutide on Platelet Reactivity in Patients with Diabetes Mellitus or Overweight with High Risk or established Cardiovascular Disease: the SEMA-PLAT Study

This study looks at how new medicines for diabetes and weight management, called Rybelsus and Wegovy, might affect tiny cells in your blood called platelets. We want to see if these medicines change how sticky platelets are in people with diabetes, who are overweight, or who have heart disease, as sticky platelets can cause problems.

Prognostic Performance of Quantitative Myocardial Perfusion Imaging Using H2[15O] Positron Emission Tomography in Coronary Artery Disease - The AQUA COR trial

This study is looking at a special heart scan called quantitative myocardial perfusion imaging using H2[15O] PET. It aims to see how well this scan can predict future heart problems like heart attacks or death in people with heart disease over up to 10 years. It will help doctors understand who is most at risk.

J1I-MC-GZBM: A Randomized, Double-Blind, Phase 3 Study to Investigate the Efficacy and Safety of LY3437943 Once Weekly Compared to Placebo in Participants with Severe Obesity and Established Cardiovascular Disease (TRIUMPH-3)

Open-Label Extension Phase 3 Study to Evaluate the Long-Term Efficacy and Safety of LIB003 in Patients With Homozygous and Heterozygous Familial Hypercholesterolemia, Cardiovascular Disease, or at High Risk for Cardiovascular Disease, on Stable Lipid-Lowering Therapy Requiring Additional Low-Density Lipoprotein Cholesterol Reduction (LIBerate-OLE)

A trial in healthy volunteers to study safety, tolerability, CS014-levels and effects in the body, after single and repeated doses of CS014, for the first time in humans.

The COlchicine HypERtENsion Trial